Does Pfizer Deserve a Place in Your Portfolio?

NYSE: PFE | Pfizer, Inc.  News, Ratings, and Charts

PFE – The biopharmaceutical giant Pfizer Inc. (PFE) has been basking in the success of its COVID-19 vaccine and breakthroughs in other therapeutics. Also, a recent FDA approval for its LORBRENA as a supplemental new drug could prove to be a major stock-price driver in the coming months. So, we think PFE is a valuable addition to one’s portfolio now. Read on to learn more.

The biopharmaceutical products manufacturer Pfizer Inc. (PFE) became an iconic leader in the pharmaceuticals industry with its breakthrough in COVID-19 vaccine development, along with German company BioNTech. 

PFE’s stock has surged 5% year-to-date, and 9.3% over the past month, on the back of solid financial prospects for its COVID-19 vaccine and double-digit operational revenue growth driven by developments in its therapeutics area.

In fact, the FDA’s recent approval of its supplemental New Drug Application (sNDA) for LORBRENA has further strengthened the pharma giant’s position in the drug development market. We think investors’ bullish sentiment on the biopharma business in general, and on PFE’s prospects, should help PFE see solid upside in the coming months.

Click here to checkout our Healthcare Sector Report for 2021

Here is what we think could shape PFE’s performance in the near term:

Favorable Biotech Industry Outlook

The COVID-19 pandemic generated heightened demand in the biopharmaceuticals industry, and the race to develop  COVID-19 vaccines specifically  accelerated the sector’s growth potential. Widespread government funding and increased R&D spending have fostered a positive environment for  biopharmaceutical companies to develop breakthrough drugs and therapeutics. As such, biopharma giant PFE is well positioned to take advantage of the strong industry backdrop and drive solid shareholder value.

PFE’s supplemental New Drug Application for LORBRENA for the treatment of people with anaplastic lymphoma recently received FDA approval. The approval should establish the company as a pioneer in delivering biomarker-driven therapies and address the needs of patients with non-small-cell lung cancer.

Reasonable Valuation

In terms of non-GAAP forward P/E, PFE is currently trading at 11.64x, 54% lower than the industry 25.29x average. The stock’s forward price/sales and price/book multiples of 3.51 and 2.93, respectively, are 52.8% and 38.7% lower than the 3,51 and 2.93  industry averages.

PFE’s 10.1x forward EV/EBITDA ratio is 41% lower than the industry average 17.11.

Impressive Financials

PFE’s revenues have increased 12% year-over-year to $11.68 billion in the fourth quarter, ended December 31, 2020. It reported $594 million in  net income, compared to a net loss of $337 million in the fourth quarter of 2019. Its EPS came in at $0.10 for the period. The company’s revenue from vaccines rose 17% from the prior-year quarter to $2.0 billion. And its  rare disease revenue grew 26% year-over-year to $865 million.

Consensus Price Target Indicates Potential Upside

Of 20 Wall Street analysts that rated the stock, two rated it Strong Buy and five rated it Buy. Analysts expect the stock to hit an average price target of $40.69 in the near term, representing a potential upside of 5.3%

POWR Ratings Indicate Solid Prospects

PFE has an overall B rating, which translates to Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree. 

Our proprietary rating system also evaluates each stock based on eight different categories. The stock has a B grade for Value, Stability and Quality. PFE’s lower-than-industry P/E ratio accounts for the Value grade. Its higher-than-industry gross profit margin is in sync with the company’s Quality grade. Also, its lower volatility justifies the Stability grade.

In addition to the grades we’ve highlighted, one  can check out PFE Ratings for the Sentiment, Growth, and Momentum here.

The stock is ranked #21 of 232 stocks in the Medical – Pharmaceuticals industry.

If you’re looking for other top-rated stocks in the same industry, with an Overall POWR Rating of A or B, you can access them here.

Bottom Line

With the COVID-19 vaccine becoming a source of recurring revenue for PFE, along with its  pipeline of new drugs and transformative medicines, it is uniquely positioned to witness strong growth in the near term. Furthermore,  the stock’s reasonable valuation and superior financials should help it perform better in the coming months. Hence, we think the stock is an ideal investment option now.

Click here to checkout our Healthcare Sector Report for 2021


PFE shares were trading at $38.58 per share on Monday morning, down $0.08 (-0.21%). Year-to-date, PFE has gained 5.95%, versus a 12.12% rise in the benchmark S&P 500 index during the same period.


About the Author: Imon Ghosh


Imon is an investment analyst and journalist with an enthusiasm for financial research and writing. She began her career at Kantar IMRB, a leading market research and consumer consulting organization. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PFEGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Top 10 Value Stocks

The S&P 500 (SPY) has shown mixed results in the last week, but if you are a value investor, then yesterday was a big day. That’s when we revealed to our readers the fatal flaws of traditional value investing and the solution to this problem—our Top 10 Value Stocks strategy. Read on below to find out more about this 3-step process and its +38.63% annual returns…

:  |  News, Ratings, and Charts

4 Top-Rated Tech Stocks to Enhance Your Portfolio

The investor rotation away from technology stocks is expected to be short-lived owing to the unabated demand for advanced technology products and services. Therefore, we think some of the biggest names in the tech industry, specifically Intel (INTC), International Business Machines Corporation (IBM), Panasonic (PCRFY), and Canon (CAJ) are solid bets at their current price levels. Read on for an explanation.

:  |  News, Ratings, and Charts

2 Casino Stocks Wall Street Loves

The easing of pandemic distancing restrictions facilitated by mass vaccinations is allowing casinos and related entertainment companies to reopen at 40-50% capacity. This, coupled with the rising popularity of online gambling, is fostering optimism among Wall Street analysts about the upside potential of Penn National Gaming (PENN) and Melco Resorts & Entertainment (MLCO). Read on.

:  |  News, Ratings, and Charts

4 Buy-Rated Financial Stocks to Snatch Up in May

Financial sector stocks have been making an impressive comeback in lockstep with the economy’s recovery. So, we think investing in the stocks of fundamentally sound Goldman Sachs (GS), Lazard (LAZ), Piper Sandler (PIPR), and Cowen (COWN) could pay off handsomely in the near term.

:  |  News, Ratings, and Charts

2 Casino Stocks Wall Street Loves

The easing of pandemic distancing restrictions facilitated by mass vaccinations is allowing casinos and related entertainment companies to reopen at 40-50% capacity. This, coupled with the rising popularity of online gambling, is fostering optimism among Wall Street analysts about the upside potential of Penn National Gaming (PENN) and Melco Resorts & Entertainment (MLCO). Read on.

Read More Stories

More Pfizer, Inc. (PFE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PFE News